Myriam Taibi

618 total citations · 1 hit paper
5 papers, 470 citations indexed

About

Myriam Taibi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Myriam Taibi has authored 5 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 1 paper in Cancer Research. Recurrent topics in Myriam Taibi's work include Lung Cancer Treatments and Mutations (4 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Myriam Taibi is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Myriam Taibi collaborates with scholars based in United States. Myriam Taibi's co-authors include Lynette M. Sholl, Patrick A. Ott, F. Stephen Hodi, Nikhil H. Ramaiya, Mizuki Nishino, Mark M. Awad, Hiroto Hatabu, Amanda J. Redig, Daniel B. Costa and Bruce E. Johnson and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and JAMA Oncology.

In The Last Decade

Myriam Taibi

5 papers receiving 464 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

2016 361 citations Mizuki Nishino, Nikhil H. Ramaiya et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Myriam Taibi

Since Specialization

Citations

This map shows the geographic impact of Myriam Taibi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myriam Taibi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myriam Taibi more than expected).

Fields of papers citing papers by Myriam Taibi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Myriam Taibi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myriam Taibi. The network helps show where Myriam Taibi may publish in the future.

Co-authorship network of co-authors of Myriam Taibi

This figure shows the co-authorship network connecting the top 25 collaborators of Myriam Taibi. A scholar is included among the top collaborators of Myriam Taibi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Myriam Taibi. Myriam Taibi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial 2016 ·Clinical Cancer Research ·Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O’Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. Johnson, Daniel B. Costa, David M. Jackman, Pasi A. Jänne	92
2	PD-1 inhibitor-related pneumonitis in advanced cancer patients. 2016 ·Journal of Clinical Oncology ·Mizuki Nishino, Nikhil H. Ramaiya, Mark M. Awad, (unknown), Myriam Taibi, Hiroto Hatabu, Patrick A. Ott, Philippe Armand, F. Stephen Hodi	2
3	PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course breakdown → 2016 ·Clinical Cancer Research ·Mizuki Nishino, Nikhil H. Ramaiya, Mark M. Awad, Lynette M. Sholl, (unknown), Myriam Taibi, Hiroto Hatabu, Patrick A. Ott, (unknown), F. Stephen Hodi	361
4	Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With AdvancedEGFRMutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial 2016 ·JAMA Oncology ·Amanda J. Redig, Daniel B. Costa, Myriam Taibi, David Boucher, Bruce E. Johnson, Pasi A. Jänne, David M. Jackman	13
5	A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression. 2015 ·Journal of Clinical Oncology ·Amanda J. Redig, Myriam Taibi, Geoffrey R. Oxnard, David Boucher, Michael S. Rabin, Judith Marcoux, Leena Gandhi, Mark S. Huberman, Deepa Rangachari, Joan Lucca, (unknown), (unknown), Bruce E. Johnson, Daniel B. Costa, Pasi A. Jänne, David M. Jackman	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact